Robert Bujak

Contemporary, mechanism-anchored biomarkers of endothelial dysfunction and oxidative stress (established and emerging)

Katarzyna Skibicka, Weronika Wesołowska, Albert Jaśniak, Robert Bujak

Background: Endothelial dysfunction and oxidative stress act together across hypertension, atherosclerosis, coronary disease and heart failure. Loss of nitric oxide (NO) signalling and excess reactive oxygen species (ROS) fuel inflammation, thrombosis and adverse remodelling Objective: To provide a contemporary, mechanism-anchored review of …

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy: Clinical Practice Update

Katarzyna Skibicka, Weronika Wesołowska, Tomasz Skibicki, Robert Bujak

Background: Chronic Chagas cardiomyopathy is an arrhythmogenic, fibrosis-prone form of heart failure that develops years after Trypanosoma cruzi infection. Standard therapy has largely been extrapolated from non-Chagas trials. Angiotensin receptor-neprilysin inhibition (ARNI) offers a biologically plausible approach by enhancing natriuretic peptide/cGMP signaling …

From VICTORIA to VICTOR: Where Vericiguat Fits in HFrEF Care

Katarzyna Skibicka, Weronika Wesołowska, Albert Jaśniak, Robert Bujak

Background. Vericiguat, an oral soluble guanylate cyclase stimulator, augments impaired NO-sGC-cGMP signaling in heart failure with reduced ejection fraction (HFrEF). The pivotal VICTORIA trial enrolled high-risk patients with recent worsening heart failure (WHF) and showed a reduction in the composite of cardiovascular …

Beta blockers after myocardial infarction without heart failure: time for a paradigm shift?

Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak

Background. The role of beta‑blockers (BBs) after myocardial infarction (MI) without heart failure (HF) and with LVEF ≥40% is uncertain in the contemporary era of PCI, dual antiplatelet therapy and high‑intensity statins. Two recent randomized trials - REBOOT‑CNIC and BETAMI-DANBLOCK - provide …

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak

Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart failure. Conventional drugs improve symptoms but do not directly address sarcomeric hypercontractility. …

Pulmonary valve infective endocarditis (PVIE) fully removed by percutaneous approach with the use of Angiovac: First report with 6 month follow-up observation

Sebastian Stefaniak, Robert Bujak, Mateusz Puślecki, Aleksander Araszkiewicz et autres

pl (code pays fourni par la source)

A clinical case of a 21-year-old patient with idiopathic acute exudative pericarditis

Łukasz Wołowiec, Daniel Rogowicz, Robert Bujak, Anna Choma et autres

act Pericarditis is a disease entity associated with the primary or secondary inflammation of its layers, which may be accompanied by the accumulation of fluid in the pericardial sac, the consequences of which depend mainly on the speed of its accumulation. The …

pl (code pays fourni par la source)

Aging Athlete's Heart: An Echocardiographic Evaluation of Competitive Sprint- versus Endurance-Trained Master Athletes

Krzysztof Kusy, Jan Błażejewski, Wojciech Gilewski, Danuta Karasek et autres

hu, pl (code pays fourni par la source)

Resveratrol and cardiovascular system—the unfulfilled hopes

Małgorzata Chudzińska, Daniel Rogowicz, Łukasz Wołowiec, Joanna Banach et autres

pl (code pays fourni par la source)

Wartość oznaczania stężeń antygenu nowotworowego Ca 125 i kopeptyny w monitorowaniu terapii chorych z zaawansowaną niewydolnością serca

Anita Woźniak-Wiśniewska, Jan Błażejewski, Robert Bujak, Łukasz Wołowiec et autres

Introduction. A search continues for new markers and new monitoring methods that would be useful in the management of patients with advanced heart failure (HF). Recent studies have shown increased levels of cancer antigen 125 (Ca 125) and copeptin in patients with …

pl (code pays fourni par la source)

Ocena wartości rokowniczej wybranych parametrów ergospirometrycznych u chorych z przewlekłą skurczową niewydolnością serca kwalifikowanych wstępnie do transplantacji serca, w obserwacji 12-miesięcznej

Jarosław Pietrzak, Wojciech Gilewski, Danuta Karasek, Jan Błażejewski et autres

Introduction. Despite recent advances in diagnosis and pharmacological treatment of cardiovascular diseases, chronic heart failure (HF) carries a poor prognosis. The identification of patients at highest risk for early death from HF is of special importance. Ergospirometric test is known to be …

pl (code pays fourni par la source)

Prognostic value of selected echocardiographic, impedance cardiographic, and hemodynamic parameters determined during right heart catheterization in patients qualified for heart transplantation

Wojciech Gilewski, Jarosław Pietrzak, Joanna Banach, Robert Bujak et autres

pl (code pays fourni par la source)